APSR2026-568

Yes
Late-Breaking
Submitted
Poster Presentation
 
AP08-010
P65
 
Format: PPTX Only
https://storage.unitedwebnetwork.com/files/1285/1220886-46904-APSR 568_439892.pdf
Format: PDF Only
06. Tuberculosis
4

No more than 15 authors can be listed.
Please ensure the authors are listed in the right order.
If there are multiple affiliations, please use the "+" button next to "Select Country/Region" to add additional affiliation fields.

Ibnu Hidayat M. Basir * Universitas Indonesia Department of Pulmonology and Respiratory Medicine, Faculty of Medicine Universitas Indonesia, Persahabatan Hospital Jakarta Indonesia
Erlina Burhan - Universitas Indonesia Department of Pulmonology and Respiratory Medicine, Faculty of Medicine Universitas Indonesia, Persahabatan Hospital Jakarta Indonesia
Riyadi Sutarto - Universitas Indonesia Department of Pulmonology and Respiratory Medicine, Faculty of Medicine Universitas Indonesia, Persahabatan Hospital Jakarta Indonesia
Euis Mutmainnah - Universitas Indonesia Department of Dermatology, Venereology and Aesthetic, Faculty of Medicine Universitas Indonesia, Persahabatan Hospital Jakarta Indonesia
 
 
 
 
 
 
 
 
 
 
 
Presenting Author Details
Ibnu Hidayat M.
Basir
ibnuhidayat91@gmail.com
+6285299434474
31-40
Indonesia
Original Research
Observation of skin hyperpigmentation improvement in patients with drug-resistant tuberculosis within one year after discontinuation of clofazimine at persahabatan hospital
Maximum 25 words
Abstract Content
Clofazimine (CFZ) is one of the key drugs in the treatment regimen for drug-resistant tuberculosis (DR-TB). However, skin hyperpigmentation is the most common adverse effect and may negatively impact patients’ quality of life and treatment adherence. To date, data on the reversibility and pattern of improvement of skin hyperpigmentation after CFZ discontinuation in DR-TB patients remain limited.
This was a prospective longitudinal study involving 36 DR-TB patients who had completed a CFZ-containing treatment regimen at Persahabatan Hospital, Jakarta, Indonesia. Dermoscopic images were obtained from the left upper arm at month 0 (at treatment completion), and at months 1, 2, 6, and 12 after discontinuation. These were compared with images at month 13, which served as a reference representing near-normal skin. The images were quantified, and the degree of skin hyperpigmentation was objectively assessed using the Skin Hyperpigmentation Index (SHI).
All patients (100%) still exhibited mild skin hyperpigmentation at month 0, with a median SHI of 1.25 (IQR 0.24). There was no significant association between median SHI at month 0 and age (p=0.250), sex (p=0.566), body mass index (p=0.398), treatment duration (p=0.702), or DR-TB diagnosis (p=0.890). The median SHI decreased over time from 1.25 (IQR 0.24) at month 0 to 1.18 (IQR 0.23) at month 1, 1.15 (IQR 0.17) at month 2, 1.06 (IQR 0.12) at month 6, and 1.02 (IQR 0.24) at month 12. Friedman test showed a significant difference across time points (χ² = 143.21; p < 0.001), and post-hoc Wilcoxon tests demonstrated significant differences between all time-point pairs (all p < 0.001). All patients (100%) showed onset of improvement within the first two months after treatment discontinuation. Complete resolution (SHI = 1) at month 12 was observed in 5 patients (13.9%), while 31 patients (86.1%) still had mild hyperpigmentation at the end of observation.
Skin hyperpigmentation associated with CFZ use is reversible, with onset of improvement occurring within the first two months after drug discontinuation. Although significant improvement occurs over time, most patients require more than one year to achieve complete resolution.
 
 
 
 
 
No
Yes
https://storage.unitedwebnetwork.com/files/1285/1220886-37089-SHI_381032.png
JPG or JPEG or PNG format ONLY
clofazimine; drug-resistant tuberculosis; skin hyperpigmentation
maximum 3 keywords and no abbreviations, separated by commas
 
356